Results of world-first viral therapy trial in Ottawa cancer patients published in Nature Researchers from the Ottawa Hospital Research Institute (OHRI), the University of Ottawa (uOttawa), Jennerex Inc. and several other

First Page		Document Content
Date: 2012-07-26 14:23:08 Oncolytic virus Viruses Ottawa Hospital Research Institute John Cameron Bell JX-594 Cancer research The Ottawa Hospital Medical research Medicine Experimental cancer treatments Cancer treatments		Results of world-first viral therapy trial in Ottawa cancer patients published in Nature Researchers from the Ottawa Hospital Research Institute (OHRI), the University of Ottawa (uOttawa), Jennerex Inc. and several other Add to Reading List Source URL: ohfoundation.ca Download Document from Source Website File Size: 30,14 KB Share Document on Facebook

	Legend Open to Accrual Pending Hepatocellular Carcinoma DocID: 17R4m - View Document
	Peretinoin (NIK-333) Study Subanalysis Gives Clue To Mechanism of Reduced Recurrence of Hepatocellular Carcinoma (HCC), To Be Presented at American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2011 DocID: ZT0U - View Document
	August 30, 2010 PRESS RELEASE Peretinoin（NIK-333）Data, the Results of the Phase II/III Trial for the Suppression of Recurrence of Hepatocellular Carcinoma (HCC), To Be DocID: ZHyL - View Document
	September 2011 Global recognition for cancer researcher at The Ottawa Hospital In a world-first cancer therapy trial, Dr. John Bell, a senior scientist at the Ottawa Hospital Research Institute (OHRI), has shown that a g DocID: GjGI - View Document
	GTSAB REPORT Recombinant DNA Advisory Committee DocID: EYVt - View Document